Layoffs

Look how many products declined in revenue and then look at those that grew, the growth was modest.



Prolia hasn't actually grown, it's only grown compared to Q3 2016. Nice try Amgen

No US growth, only ex-US. How does that $10.5B acquisition look for a product 5 years post launch and still not a $1B drug worldwide.

See the bars, they are flat....no growth!



Neulasta trending down!

Neupogen - even worse. Bars going down like Justin Bieber's career!

The cow is drying up!

Flat growth at best....it's like a slow drip

Fast drip!

Barely growth!

At this rate, Repatha will hit a $1B a year in it's last year before patent expiry.

So outcomes gives you 2X sales meaning a 5% approval is now 10%... congrats Amgen. This is like being proud of your kid for D instead of their usual F grade.



Amgen's best R&D asset is mostly owned by AstraZeneca! Enbrel reps hoping Amgen buys AZ so they don't have to talk about Enbrel any longer.

Can’t say it’s a troll because it’s actual amgen data. The decline has been happening ever since amgen couldn’t price increase 20%+ year over year.

All the positive growth came from stellar reps and Amgen cannot retain these amazing reps bc of shitty culture and and cheating them out of their bonus. The Average tenurship of new reps coming to Amgen is 2.2 years at best. Look at the training department, it is a revolving door of training new hires! Wake up Amgen, work on retaining reps that are performers and focus on Amgen Culture. The biggest cost to Amgen is constant training of new hires.

Dat true.

anonymous said:

Can’t say it’s a troll because it’s actual amgen data. The decline has been happening ever since amgen couldn’t price increase 20%+ year over year.

Click to expand...